Skip to content
Screener

BioCryst Pharmaceuticals BCRX Business Segments — Total revenues

Similar metrics at other companies

International Money Express logo
IMXIReportable Segment — Total revenues
$121.95M-15.5%
nCino, Inc. logo
NCNOReportable Segment — Total revenues
$159.41M+10.6%
Intuitive Machines, Inc. logo
LUNRReportable Segment — Total revenues
$186.73M+199%
Sonida Senior Living logo
SNDAReportable Segment — Total revenues
$110.12M+38.9%
BJ's Wholesale Club Holdings, Inc. logo
BJReportable Segment — Total revenues
$5.66B+9.9%
Calix logo
CALXReportable Segment — Total revenues
$293.33M+21.3%

Other financials

Income statement

See full
Revenue$218.3M+33.6%
Gross profit$214.4M+33.5%
Operating income$98.5M+231%
Net income$78.4M+1,442%
EPS (diluted)$0.30+1,400%

Balance sheet

See full
Cash & equivalents$156.4M+73.9%
Total debt$410.9M+59.9%
Total equity-$454.3M-7.8%
Total assets$557.9M+22.0%

Cash flow

See full
Operating cash flow$104.3M+153%
CapEx$209.0K+16.8%
Free cash flow$104.1M+153%

Valuation

See full
Market cap$2.38B+31.6%
Enterprise value$2.63B+33.4%
P/S2.5×-0.7×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-33.3%-43.0pp
Net margin-40.9%-50.2pp
FCF margin39.7%

Returns & leverage

See full
Return on equity-882.8%
Debt / equity0.1×
Current ratio2.3×+0.1×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.

The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:04 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053300
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Revenues$218,250$163,353$374,663$308,887
Less1:
Cost of product sales3,8402,7989,2177,366
Acquired in-process research and development697,761
Research and development (excluding stock-based compensation)
Navenibart17,32827,069
BCX177255,2403,3167,1475,772
Berotralstat1,6114,7663,4076,640

Item 1. Financial Statements (Unaudited):

FAQ

What is BioCryst Pharmaceuticals's business segments — total revenues?
BioCryst Pharmaceuticals (BCRX) reported business segments — total revenues of $218.25M in Q2 2026.
How has BioCryst Pharmaceuticals's business segments — total revenues changed year-over-year?
BioCryst Pharmaceuticals's business segments — total revenues increased by 33.6% year-over-year, from $163.35M to $218.25M.
What is the long-term trend for BioCryst Pharmaceuticals's business segments — total revenues?
Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's business segments — total revenues has grown at a 47.8% compound annual growth rate (CAGR), from $270.83M to $874.84M.
What does business segments — total revenues mean?
Represents the total gross income generated by the business segment from its primary operations, including product sales and licensing. This metric serves as a key indicator of the segment's market demand and commercial success in its specific therapeutic areas.

Ask your AI about BioCryst Pharmaceuticals's business segments — total revenues.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude